Evidence map›Paper›PMID 25054431›Full record

ArticleClinical pharmacology and therapeutics2014

Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer.

X Pu, L Wang, J Y Chang, M A T Hildebrandt, Y Ye, C Lu, H D Skinner, N Niu, G D Jenkins, R Komaki and 4 more

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Radiation-Induced Lung Injury (RILI).Frontiers in oncology · 2019
    Review
  11. Article
  12. Article
  13. Genetic variants in the ITGB6 gene is associated with the risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

X PuDepartment of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
L WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
J Y ChangDepartment of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
M A T HildebrandtDepartment of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Y YeDepartment of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
C LuDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
H D SkinnerDepartment of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
N NiuDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
G D JenkinsDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
R KomakiDepartment of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
J D MinnaHamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
J A RothDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
R M WeinshilboumDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
X WuDepartment of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · USMayo Clinic · USMayo Clinic in Florida · USThe University of Texas Southwestern Medical Center · USWinnMed · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
Genome-Wide Association Analysis of Bladder CancerU01CA127615 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIFENG · 2008 to 2012
$5.1M
Lung Cancer Chemoradiation: Predictors of SurvivalR01CA111646 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIFENG · 2005 to 2009
$2.9M
Pharmacogenomics and Mechanisms of Cytidine AnaloguesR01CA138461 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2009 to 2013
$1.5M
NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS P50CA070907NCI NIH HHS R01 CA111646NCI NIH HHS R01-CA111646NCI NIH HHS R01-CA127615NCI NIH HHS R01 CA138461NCI NIH HHS R01-CA138461NCI NIH HHS U01 CA127615NIGMS NIH HHS U19 GM061388NIGMS NIH HHS U19-GM61388
6 · The paper itself

Abstract

Definitive radiotherapy improves locoregional control and survival in inoperable non-small cell lung cancer patients. However, radiation-induced toxicities (pneumonitis/esophagitis) are common dose-limiting inflammatory conditions. We therefore conducted a pathway-based analysis to identify inflammation-related single-nucleotide polymorphisms associated with radiation-induced pneumonitis or esophagitis. A total of 11,930 single-nucleotide polymorphisms were genotyped in 201 stage I-III non-small cell lung cancer patients treated with definitive radiotherapy. Validation was performed in an additional 220 non-small cell lung cancer cases. After validation, 19 single-nucleotide polymorphisms remained significant. A polygenic risk score was generated to summarize the effect from validated single-nucleotide polymorphisms. Significant improvements in discriminative ability were observed when the polygenic risk score was added into the clinical/epidemiological variable-based model. We then used 277 lymphoblastoid cell lines to assess radiation sensitivity and expression quantitative trait loci (eQTL) relationships of the identified single-nucleotide polymorphisms. Three genes (PRKCE, DDX58, and TNFSF7) were associated with radiation sensitivity. We concluded that inflammation-related genetic variants could contribute to the development of radiation-induced toxicities.

Indexed as

Polymorphism, Single NucleotideAgedCarcinoma, Non-Small-Cell LungFemaleGenetic VariationHumansInflammationLung NeoplasmsMaleMiddle AgedRadiation ToleranceRadiotherapy

Identifiers

PMID25054431
PMCPMC4206576
OpenAlexW2000653760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.